A simple detection system for adenovirus receptor expression using a telomerase-specific replication-competent adenovirus

Gene Therapy

Volumn 20, Issue 1, 2013, Pages 112-118

  Sasaki, T ^a   Tazawa, H ^a,b   Hasei, J ^a   Osaki, S ^a   Kunisada, T ^a   Yoshida, A ^a   Hashimoto, Y ^a   Yano, S ^a   Yoshida, R ^a   Kagawa, S ^a   Uno, F ^a   Urata, Y ^c   Ozaki, T ^a   Fujiwara, T ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

adenovirus; GFP; oncolytic virus; sarcoma; telomerase

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GREEN FLUORESCENT PROTEIN; TELOMERASE;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; ENZYME SPECIFICITY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDIATOR; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; TUMOR BIOPSY; TUMOR CELL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; CELL LINE, TUMOR; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; ONCOLYTIC VIRUSES; TELOMERASE; TRANSCRIPTION, GENETIC; TRANSFORMATION, GENETIC; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84871980017     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.213     Document Type: Article

References (47)

1. Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005; 37: 33-43 (Pubitemid 40342423)
2. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006; 2: 137-143
3. Yamamoto M, Curiel DT. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18: 243-250
4. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 2221-2232 (Pubitemid 28265061)
5. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 763-771 (Pubitemid 29239055)
6. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 2006; 97: 554-561 (Pubitemid 43811599)
7. Fujiwara T, Tanaka N, Kanazawa S, Ohtani S, Saijo Y, Nukiwa T et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 1689-1699 (Pubitemid 46622140)
8. Fujiwara T, Urata Y, Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 2007; 7: 191-201 (Pubitemid 46348634)
9. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8: 12-28
10. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323 (Pubitemid 27114163)
11. Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirusmediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-2373 (Pubitemid 28523985)
12. Hutchin ME, Pickles RJ, Yarbrough WG. Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum Gene Ther 2000; 11: 2365-2375
13. You Z, Fischer DC, Tong X, Hasenburg A, Aguilar-Cordova E, Kieback DG. Coxsackievirus-adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression. Cancer Gene Ther 2001; 8: 168-175 (Pubitemid 32322256)
14. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002; 62: 3812-3818 (Pubitemid 34728866)
15. Kim M, Zinn KR, Barnett BG, Sumerel LA, Krasnykh V, Curiel DT et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002; 38: 1917-1926 (Pubitemid 35247478)
16. Qin M, Chen S, Yu T, Escuadro B, Sharma S, Batra RK. Coxsackievirus adenovirus receptor expression predicts the efficiency of adenoviral gene transfer into nonsmall cell lung cancer xenografts. Clin Cancer Res 2003; 9: 4992-4999 (Pubitemid 37323306)
17. Douglas JT, Kim M, Sumerel LA, Carey DE, Curiel DT. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817 (Pubitemid 32174383)
18. Fuxe J, Liu L, Malin S, Philipson L, Collins VP, Pettersson RF. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 2003; 103: 723-729 (Pubitemid 36110227)
19. Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY et al. Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid 2005; 15: 977-987 (Pubitemid 41475707)
20. Anders M, Rosch T, Kuster K, Becker I, Hofler H, Stein HJ et al. Expression and function of the coxsackie and adenovirus receptor in Barrett's esophagus and associated neoplasia. Cancer Gene Ther 2009; 16: 508-515
21. Korn WM, Macal M, Christian C, Lacher MD, McMillan A, Rauen KA et al. Expression of the coxsackievirus-and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther 2006; 13: 792-797 (Pubitemid 44100492)
22. Gu W, Ogose A, Kawashima H, Ito M, Ito T, Matsuba A et al. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res 2004; 10: 3831-3838 (Pubitemid 38697619)
23. Kawashima H, Ogose A, Yoshizawa T, Kuwano R, Hotta Y, Hotta T et al. Expression of the coxsackievirus and adenovirus receptor in musculoskeletal tumors and mesenchymal tissues: efficacy of adenoviral gene therapy for osteosarcoma. Cancer Sci 2003; 94: 70-75 (Pubitemid 36575861)
24. Rice AM, Currier MA, Adams LC, Bharatan NS, Collins MH, Snyder JD et al. Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J Pediatr Hematol Oncol 2002; 24: 527-533 (Pubitemid 36004538)
25. Matsumoto K, Shariat SF, Ayala GE, Rauen KA, Lerner SP. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005; 66: 441-446 (Pubitemid 41138121)
26. Anders M, Vieth M, Rocken C, Ebert M, Pross M, Gretschel S et al. Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br J Cancer 2009; 100: 352-359
27. Yamamoto S, Yoshida Y, Aoyagi M, Ohno K, Hirakawa K, Hamada H. Reduced transduction efficiency of adenoviral vectors expressing human p53 gene by repeated transduction into glioma cells in vitro. Clin Cancer Res 2002; 8: 913-921 (Pubitemid 34742125)
28. Tango Y, Taki M, Shirakiya Y, Ohtani S, Tokunaga N, Tsunemitsu Y et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackieadenovirus receptors in human lung cancer cells. Cancer Sci 2004; 95: 459-463 (Pubitemid 38832692)
29. Sasaki T, Tazawa H, Hasei J, Kunisada T, Yoshida A, Hashimoto Y et al. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. Clin Cancer Res 2011; 17: 1828-1838
30. Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004; 10 (1 Pt 1): 285-292 (Pubitemid 38114191)
31. Hashimoto Y, Watanabe Y, Shirakiya Y, Uno F, Kagawa S, Kawamura H et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008; 99: 385-390 (Pubitemid 351228496)
32. Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med 2006; 12: 1213-1219 (Pubitemid 44527360)
33. Kishimoto H, Urata Y, Tanaka N, Fujiwara T, Hoffman RM. Selective metastatic tumor labeling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther 2009; 8: 3001-3008
34. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 2009; 119: 3172-3181
35. Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T et al. In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 2009; 106: 14514-14517
36. Feero WG, Rosenblatt JD, Huard J, Watkins SC, Epperly M, Clemens PR et al. Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther 1997; 8: 371-380 (Pubitemid 27140540)
37. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5: 796-806 (Pubitemid 41400779)
38. Hoffman RM, Yang M. Subcellular imaging in the live mouse. Nat Protoc 2006; 1: 775-782
39. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791
40. Marsman WA, Buskens CJ, Wesseling JG, Offerhaus GJ, Bergman JJ, Tytgat GN et al. Gene therapy for esophageal carcinoma: the use of an explant model to test adenoviral vectors ex vivo. Cancer Gene Ther 2004; 11: 289-296 (Pubitemid 41184348)
41. Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T et al. A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res 2005; 11: 351-360 (Pubitemid 40075815)
42. Zeimet AG, Muller-Holzner E, Schuler A, Hartung G, Berger J, Hermann M et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Therapy 2002; 9: 1093-1100
43. Kuster K, Koschel A, Rohwer N, Fischer A, Wiedenmann B, Anders M. Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1alpha. Cancer Gene Ther 2010; 17: 141-146
44. Seidman MA, Hogan SM, Wendland RL, Worgall S, Crystal RG, Leopold PL. Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle. Mol Ther 2001; 4: 13-21 (Pubitemid 32684697)
45. Hotta T, Motoyama T, Watanabe H. Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol Jpn 1992; 42: 595-603
46. Kawashima H, Ogose A, Gu W, Nishio J, Kudo N, Kondo N et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet 2005; 161: 28-35 (Pubitemid 41096048)
47. Kunisada T, Miyazaki M, Mihara K, Gao C, Kawai A, Inoue H et al. A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer 1998; 77: 854-859 (Pubitemid 28378133)